Transdermal drug delivery system for delivering drugs to a patient - Patents.com
The EthoGel-Applicator system addresses inefficiencies in transdermal drug delivery by using a hydrogel-like carrier with enhancers and an applicator design to enhance drug penetration, achieving controlled and efficient delivery of NSAIDs.
Patent Information
- Application Number
- JP2023568258
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-08
- Filing Date
- 2022-11-08
- Publication Date
- 2024-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current transdermal drug delivery systems, including TD patches and topical agents, face limitations in delivering drugs at a constant rate, especially for high doses, and lack control over drug delivery across the skin, leading to inefficiencies and potential gastrointestinal side effects from oral NSAIDs.
A transdermal drug delivery system using an EthoGel-Applicator (EGATDDS) with a hydrogel-like carrier containing skin penetration enhancers and stabilizers, applied via an applicator with a rim and blunt spikes, creates an occlusive environment to enhance drug penetration and delivery.
The system achieves controlled and efficient drug delivery, with fluxes of 5-324 μg/cm²/h for diclofenac and 25-1337 μg/cm²/h for ibuprofen, overcoming limitations of traditional systems and reducing systemic adverse effects.
Smart Images

Figure 2024540701000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates generally to medical and laboratory equipment and, more particularly, to methods, systems, devices and instruments for facilitating transdermal delivery of drugs to a patient. (Related Applications) This application claims priority to U.S. Provisional Patent Application (63 / 277,098), filed November 8, 2022. [Background technology]
[0002] The medical and testing equipment sector is of technological importance to multiple industries, businesses and individuals.
[0003] Transdermal (TD) drug delivery includes two major technology categories: TD patches and topicals. TD patches have a definite skin contact area, allowing for more precise drug administration from the drug-containing medium on the patch through the skin of the user, and further protecting the patch's drug delivery medium during use. Important TD patch products include Duragesic® (fentanyl), Lidoderm (lidocaine), and Burtrans® (buprenorphine) for pain management, Ortho Evra (ethinyl estradiol and norelgestromin) as a contraceptive, Daytrana® (methylphenidate) for ADHD, and Neupro® (rotigotine) for Parkinson's disease.
[0004] Topical preparations are applied to specific areas of the skin, and most are intended to affect only the area where they are applied. Examples include local anesthetics (lidocaine, prilocaine), Penside (diclofenac) for pain from osteoarthritis, and Lotrisone (betamethasone, clotrimazole) for itching, swelling, and redness of the skin. An exception is Elestrin (estradiol), an example of transdermal drug delivery using a topical agent for vasomotor symptoms (hot flashes) due to menopause. However, topical agents generally lack a mechanism to control the rate of drug delivery through a given area of the user's skin.
[0005] Furthermore, nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely prescribed drugs in the world. There are more than 20 types of NSAIDs on the market, most of which are oral and some are topical. Ibuprofen is an NSAID and is widely used to reduce fever in pediatric patients. It is estimated that 20 percent of emergency visits to the pediatric hospital are due to fever (Alpern ER, Henretig FM. Fever. Fleisher GR, Ludwg S, Henretig FM, eds. Textbook of Pediatric Emergency Medicine. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. 295-306). Therefore, a TD ibuprofen formulation that can precisely deliver the active ingredient through the skin, especially targeted at infants and young children, could be of great benefit to their health. Diclofenac has also been approved as a topical analgesic prescription drug in the United States.
[0006] There are risks associated with the use of oral NSAIDs for long-term pain management. A 1998 report on gastrointestinal problems caused by oral NSAIDs reported that of the 30 million Americans who regularly use NSAIDs, approximately 107,000 are hospitalized each year for gastrointestinal complications due to NSAIDs (Singh G. Am J Med. 1998; 105 (1B):31S-8S). Of these, an estimated 16,500 people die from NSAID-related complications (Singh G, Rosen Ramey D. J Rheumatol Suppl 1998; 51:8-16).
[0007] On the other hand, clinical results have demonstrated that topical NSAIDs are effective as analgesics while avoiding gastrointestinal side effects. According to a 2015 Cochrane review of 61 clinical studies involving approximately 8,400 patients, topical NSAIDs including diclofenac, ibuprofen, ketoprofen, piroxicam, and indomethacin have been shown to provide analgesic effects in patients with musculoskeletal injuries (acute symptoms) such as sprains, strains, and overload injuries (Derry_S, Moore_RA, Gaskell_H, McIntyre_M, Wi_en_PJ. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD007402). No systemic adverse events were reported in these studies. Another Cochrane review in 2016 of 39 clinical trials involving approximately 10,600 patients with chronic diseases concluded that topical agents containing diclofenac and ketoprofen "may provide a good level of pain relief beyond that of carriers in osteoarthritis in a small number of people, but there is no evidence for other chronic pain conditions." No data were available on serious gastrointestinal adverse events (Derry S, Conaghan P, Da Silva JAP, Wiffen PJ, Moore RA. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD007400.).
[0008] The inadequacy of topical NSAIDs to relieve pain in chronic patients is not surprising given the fact that to be effective, a certain amount of the active ingredient must penetrate the skin and reach the site of inflammation or pain.
[0009] Currently available TD patches are limited in their ability to deliver drugs at a constant rate. For example, the drug delivery amounts in 24 hours for buprenorphine as an active ingredient, ritigotine as an active ingredient, and rivastigmine as an active ingredient are 0.12 mg, 1 mg, and 4.5 mg, respectively. The delivery amount cannot be easily increased due to the nature of the active ingredients and other factors. For example, firstly, a single TD patch can only deliver a limited amount of drug delivery carrier along with the drug. In addition, the choice of drug delivery vehicle is limited, usually consisting of an adhesive system (matrix type). Some types of TD patches require additional barriers (e.g., membranes for reservoir systems), further limiting the drug delivery rate. These characteristics mean that patches are not suitable drug delivery systems for drugs that require high doses (ranging from 10 mg to 100 mg per 24 hours) to reach effective levels in the human body. Topical agents perform even worse as transdermal drug delivery systems. In a recent study, 12 topical preparations (six of each) containing diclofenac or ibuprofen were tested for in vitro permeation through human skin. Commercially available formulations included emulsions, creams, and gels containing 1% diclofenac or 5-10% ibuprofen. Skin permeability varied greatly between preparations. The cumulative amount of drug permeated through the skin over 24 hours ranged from 119 to 747 ng / cm2 for products containing 1% diclofenac and 5944 to 9293 ng / cm2 for products containing 5% ibuprofen (Pradal J. Journal of Pain Research. 2020:13, 2805-2814). This result indicates that drug penetration is very limited in these products.
[0010] There are various factors that control the drug delivery rate of TD formulations, as follows: 1) Physical / chemical properties of the active ingredient - TD drug delivery is a process of distribution and diffusion of drug molecules. The presence of a skin barrier, i.e., the stratum corneum (SC), is a limiting factor for the type of drug suitable for TD delivery. For example, the molecular weight of the drug must be less than 500 Daltons. 2) Dosage form - Most topical preparations are semi-solid preparations, e.g., gels, creams, ointments, and emulsions, which vary widely in their ability to deliver drugs transdermally. In these products, permeation enhancers are often employed to facilitate drug delivery. 3) Drug solubility - The rate of drug penetration in TD drug delivery is positively correlated with the concentration of the active ingredient (dissolved) in the carrier of the topical formulation. 4) Patient's skin condition - The SC layer of the skin best protects the human body when it is in a dry state, but it is also a condition that prevents drugs from penetrating the skin. The application of a patch or topical preparation changes the skin condition to some extent, and the partial hydration of the SC layer of the skin enhances drug penetration. 5) Drug application environment – TD patches create an occlusive environment during use, leading to hydration of the SC layer. Some topical agents, e.g. ointments, can create a certain degree of occlusive environment.
[0011] Moreover, various forms of TD patches have been widely accepted as medical products and play an important role in the medical community, but their commercial production requires advanced facilities and is costly compared with topical agents, and the types and amounts of drugs that can be delivered by TD patches are still very limited.
[0012] Thus, there is a need for improved methods and systems for facilitating the delivery of medications to patients that may overcome one or more of the problems and limitations discussed above. Summary of the Invention
[0013] This Summary is intended to introduce some of the concepts described below in a simplified form in the Detailed Description. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
[0014] Some embodiments disclose a transdermal drug delivery system for delivering a drug to a patient. The transdermal drug delivery system may further include an applicator attached to a backing layer of a medical tape via an adhesive layer and a topical formulation containing an appropriate amount of a drug. When the transdermal drug delivery system is applied to the patient's skin, the appropriate amount of the drug penetrates the skin. The topical formulation may further include an EthoGel formulation that includes an active ingredient in a hydrogel-like carrier at an appropriate concentration for transdermally delivering a predetermined dose of the drug, and two gelling agents that define the hydrogel-like physical properties of the carrier in the presence of two skin penetration enhancers that also act as solvents / co-solvents. The topical formulation may further include a buffer to enhance the solubility of the active ingredient in the formulation, a stabilizer, and various components in optimized ratios to maintain the chemical and physical stability of the drug delivery vehicle. The applicator may further include a rim consisting of a boundary that defines an enclosed space and a blunt spike present on the bottom surface of the applicator. Furthermore, the height of the rim may be greater than the height of the blunt spike. Additionally, the topical formulation may be loaded into the enclosed space of the applicator between the spike and the rim.
[0015] Both the foregoing summary and the following detailed description are exemplary and explanatory only. Thus, the foregoing summary and the following detailed description are not to be taken in a limiting sense. Furthermore, features and variations may be provided in addition to those set forth herein. For example, embodiments may be directed to combinations or subcombinations of various features described in the detailed description. [Brief description of the drawings]
[0016] The accompanying drawings, which are incorporated in and constitute a part of this disclosure, illustrate various embodiments of the present disclosure. The drawings may depict various trademarks and copyrighted material in which the applicant owns rights. Additionally, the drawings may contain other marks owned by third parties, which are used for illustrative purposes only. All rights in the various trademarks and copyrighted material contained herein are owned by the applicant, except as otherwise provided by their respective owners. The applicant retains and reserves all rights in the trademarks and copyrighted material contained herein and grants permission to reproduce them for any purpose other than in connection with the reproduction of the granted patent.
[0017] Additionally, the figures may contain text (captions) that describe particular embodiments of the present disclosure, which text is included for the purposes of illustrating, not limiting, and describing the particular embodiments detailed in the present disclosure.
[0018] [Figure 1] FIG. 2 is a top perspective view of the present invention. [Diagram 2] FIG. 2 is a bottom perspective view of the present invention. [Diagram 3] FIG. 2 is a side view of the present invention. [Figure 4] FIG. 4 is a cross-sectional view taken along line 4-4 in FIG. [Diagram 5] FIG. 1 is a block diagram showing the configuration of a topical drug according to the present invention. [Figure 6] 1 is a schematic diagram of a transdermal drug delivery system showing the structure of an applicator, according to some embodiments. [Figure 7] 1 is a close-up view of a transdermal drug delivery system showing placement of an applicator on a piece of medical tape, according to some embodiments. [Figure 8] 1 is a graphical representation showing in vitro skin permeation of ibuprofen using EthoGel formulation Example 1 and porcine abdominal skin, according to some embodiments. [Figure 9] FIG. 2 is a graphical representation showing in vitro skin permeation of ethanol using EthoGel formulation Example 1 and porcine abdominal skin, according to some embodiments. [Figure 10] FIG. 2 is a graph showing in vitro skin permeation of glycerin using EthoGel formulation Example 1 and porcine abdominal skin, according to some embodiments. [Figure 11] FIG. 2 is a graphical representation showing in vitro skin permeation of diclofenac using EthoGel formulation Example 2 and porcine abdominal skin, according to some embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] All figures in the drawings are for the purpose of illustrating selected versions of the invention and are not intended to limit the scope of the invention.
[0020] The present invention is a system for transdermal delivery of a drug to a patient. The present invention may be used for patients suffering from arthritis or acute or chronic musculoskeletal pain. As seen in Figures 1 to 5, a preferred embodiment of the present invention comprises a backing layer 101, an adhesive layer 102, a topical applicator 103, a dose of drug 108, and a dose of topical carrier 109. The backing layer 101 is used as a structural platform for connecting other components of the present invention. The backing layer 101 is preferably a medical tape and is preferably impermeable to prevent drug solution from seeping through the backing layer 101. The adhesive layer 102 adheres the topical applicator 103 to the backing layer 101. The topical applicator 103 is used to hold and dispense the dose of drug 108 together with the dose of topical carrier 109. The topical applicator 103 is preferably made of a polycarbonate material. The amount of medication 108 is any medication that can be topically applied to the patient's skin. The amount of medication 108 can be, but is not limited to, a nonsteroidal anti-inflammatory drug (NSAID). The amount of topical carrier 109 can facilitate application and hold the appropriate amount of medication 108. The amount of topical carrier 109 can be, but is not limited to, a gel, cream, foam, lotion, or ointment.
[0021] The topical applicator 103 is also configured to aid in easy topical application and retention of the appropriate amount of medication 108. The topical applicator 103 includes a flat applicator body 104, a plurality of blunt spikes 105, and a containment rim 106. The flat applicator body 104 is used as a structural platform that connects the other components of the topical applicator 103 together. The flat applicator body 104 may be sized and shaped to optimally deliver the appropriate amount of medication 108 through the patient's skin. For example, the perimeter shape of the flat applicator body 104 may be, but is not limited to, a square shape, a rectangular shape, a circular shape, or an oval shape. The containment rim 106 is used as a peripheral boundary for the appropriate amount of medication 108 and the appropriate amount of topical carrier 109. The height of the containment rim 106 from the flat applicator body 104 is preferably between 600 μm (micrometers) and 3500 μm (micrometers). The multiple blunt spikes 105 are used to increase the available surface area of the topical applicator 103 to hold an appropriate amount of the drug 108 and topical carrier 109. The total number of spikes of the multiple blunt spikes 105 may be determined to optimally deliver the appropriate amount of drug 108 through the patient's skin.
[0022] The general configuration of the aforementioned components allows the present invention to effectively and efficiently deliver a drug to a patient through the patient's skin. The appropriate amount of drug 108 and the appropriate amount of topical carrier 109 are homogenously mixed as a topical drug 107, allowing the appropriate amount of topical carrier 109 to dilute, hold, and dispense the appropriate amount of drug 108. The adhesive layer 102 is disposed between the backing layer 101 and the flat applicator body 104, such that the adhesive layer 102 allows the flat applicator body 104 to connect across and to the backing layer 101. This arrangement between the backing layer 101, the adhesive layer 102, and the flat applicator body 104 provides the necessary structural support for the topical applicator 103 when a topical drug 107 is administered to a patient using the present invention. The containment rim 106 and the plurality of blunt spikes 105 are disposed adjacent the flat applicator body 104 on the opposite side from the backing layer 101 such that the containment rim 106 and the plurality of blunt spikes 105 securely hold the topical medication 107 proximate to the patient's skin for easy dispensing. The plurality of blunt spikes 105 are connected onto the flat applicator body 104, distributed throughout the flat applicator body 104, and point away from the flat applicator body 104. This arrangement of the plurality of blunt spikes 105 allows the topical applicator 103 to uniformly increase its available surface area, thereby allowing the topical applicator 103 to hold a greater amount of the topical medication 107 between the plurality of blunt spikes 105. The containment rim 106 is connected to the periphery of the flat applicator body 104 and disposed around the plurality of blunt spikes 105. This arrangement of the containment rim 106 enables the topical applicator 103 to circumscribe the topical medication 107 between the multiple blunt spikes 105, such that the external applicator 103 can retain the topical medication 107 within the containment rim 106.
[0023] The amount of topical carrier 109 is preferably comprised of a hydrogel-like carrier. Thus, the amount of topical carrier 109 may include at least one predetermined amount of gelling agent 114, at least one predetermined amount of skin penetration enhancer 110, at least one predetermined amount of buffering agent 111, at least one amount of stabilizer 112, and at least one amount of water 113. Furthermore, the at least one predetermined amount of gelling agent 114, at least one predetermined amount of skin penetration enhancer 110, at least one predetermined amount of buffering agent 111, at least one predetermined amount of stabilizer 112, and water 113 are homogeneously mixed to form a hydrogel-like carrier.
[0024] The first embodiment of the topical agent 107 is a hydrogel-like carrier having ibuprofen, and thus the amount of drug 108 is a predetermined amount of ibuprofen. The at least one gelling agent 114 includes a predetermined amount of xanthan gum and a predetermined amount of carbomer. The at least one amount of skin penetration enhancer 110 includes a predetermined amount of ethanol and a predetermined amount of glycerin. The at least one amount of a predetermined amount of a buffering agent includes sodium carbonate. The at least one amount of a stabilizer 112 is a predetermined amount of polyethylene glycol. Furthermore, the composition ratio of the topical agent 107 of the first embodiment is preferably as follows: The amount of ibuprofen is about 4.0 wt% (weight percent) based on the weight of the topical agent 107. The amount of water 113 is about 41.0 wt% based on the topical agent 107. The amount of xanthan gum is about 1.0 wt% based on the topical agent 107. The amount of carbomer is about 0.2 wt% based on the topical agent 107. The amount of ethanol is about 40.0 wt % of the topical agent 107. The amount of glycerin is about 10.5 wt % of the topical agent 107. The amount of sodium carbonate is about 0.35 wt % of the topical agent 107. The amount of polyethylene glycol is about 3 wt % of the topical agent 107. With regard to the above compositional percentages of the first embodiment of the topical agent 107, the term "about" preferably means within an error range of ±0.005 wt %.
[0025] The second embodiment of the topical agent 107 is a hydrogel-like carrier having diclofenac, and thus the amount of the drug 108 is a predetermined amount of diclofenac. The at least one gelling agent 114 includes a predetermined amount of xanthan gum and a predetermined amount of carbomer. The at least one predetermined amount of the skin penetration enhancer 110 includes a predetermined amount of ethanol and a predetermined amount of glycerin. The at least one buffering agent includes sodium carbonate. Furthermore, the composition ratio of the topical agent 107 of the second embodiment is preferably as follows: The amount of diclofenac is about 1.0 wt% of the topical agent 107. The amount of water 113 is about 37.92 wt% of the topical agent 107. The amount of xanthan gum is about 0.80 wt% of the topical agent 107. The amount of carbomer is about 0.78 wt% of the topical agent 107. The amount of ethanol is about 38.8 wt% of the topical agent 107. The amount of glycerin is about 20.0 wt % of the topical agent 107. The amount of sodium carbonate is about 0.70 wt % of the topical agent 107. With respect to the aforementioned composition percentages of the second embodiment of the topical agent 107, the term "about" preferably means within an error range of ±0.005 wt %.
[0026] (supplementary explanation) The present disclosure describes methods, systems, devices, and equipment for facilitating transdermal drug delivery to a patient. Additionally, the disclosed systems may include the EthoGel-Applicator Transdermal Drug Delivery System (EGATDDS), which has been developed to deliver nonsteroidal anti-inflammatory drugs (NSAIDs) and other drugs to a patient. Additionally, NSAID-containing formulations may include a hydrogel-like carrier and be intended for use as pain relievers for arthritis patients and antipyretics for pediatric patients, where the former application favors local drug delivery while the latter requires the active ingredient to reach the systemic circulation. The EGATDDS may be combined with an EthoGel formulation consisting of up to 50% (w / w) (by weight) ethanol or up to 70% (w / w) ethanol + glycerin combination, which are utilized as the primary / co-solvents in the carrier and as skin permeation enhancers. By adjusting the content and ratio of the two enhancers, it may be possible to make the skin a drug reservoir to retain the drug locally or to maximize drug penetration throughout the skin to facilitate systemic drug delivery. To make the transdermal drug delivery system effective, the EthoGel formulation can be applied in combination with a disk-shaped applicator that is attached to a backing layer of medical tape via an adhesive layer and applied onto the patient's skin to create an occlusive microenvironment to ensure the desired rate of drug delivery while minimizing evaporation of volatile components in the EthoGel formulation.
[0027] Further, the disclosed transdermal drug delivery system can include an EthoGel formulation, which is a topical formulation of a drug in a hydrogel-like carrier utilizing ethanol and glycerin as primary / co-solvents, and an applicator attached to a backing layer of a medical tape via an adhesive layer. Further, the applicator can include a rim for defining an enclosed space, the rim having blunt spikes on a surface of the applicator, and the EthoGel formulation filling the space on the applicator between the spikes and the rim.
[0028] Additionally, the disclosed methods may include delivering the drug in an EthoGel formulation to a patient by applying a transdermal drug delivery system to the patient's skin.
[0029] Furthermore, the EthoGel-Applicator Transdermal Drug Delivery System (EGATDDS) may be designed to achieve improved and more controllable TD drug delivery compared to TD patches and topicals. In vitro permeation studies were performed to demonstrate that the system can deliver ibuprofen and diclofenac through porcine abdominal skin. Furthermore, the EthoGel formulation may contain ibuprofen or diclofenac as active ingredients in a hydrogel-like carrier. Furthermore, the permeation rate can be determined using attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and multivariate modeling. The disclosed method allows for simultaneous quantification of the skin permeation enhancer as well as the active ingredient. Furthermore, the EGATDDS can achieve fluxes of 5-324 μg / cm2 / H and 25-1337 μg / cm2 / H for diclofenac and ibuprofen, respectively. Flux results are obtained based on comprehensive in vitro permeation studies using porcine abdominal skin samples (normalized to correspond to a skin thickness of 0.10 cm). For example, for ibuprofen alone, 36 formulations were tested and optimized to deliver milligrams of active ingredient per hour transdermally when using an applicator of 10 cm2 or larger.
[0030] Compared with currently available topical NSAID preparations, EGATDDS has advantages. For example, the EthoGel formulation contains high concentrations of multiple skin penetration enhancers, which accelerate TD drug delivery. In addition, the formulation provides high solubility for the active ingredients. Moreover, the formulation can form a physically stable gel even in the presence of very high concentrations of organic solvents (i.e., ethanol and glycerin). Moreover, EGATDDS provides an occlusive environment, which can control the degree of skin hydration and reduce the barrier capacity of the SC layer, thereby facilitating drug penetration and permeation.
[0031] Furthermore, the efficacy of EthoGel formulations to optimize transdermal delivery of active ingredients from dosage forms suitable for drug administration can be evaluated before preclinical or clinical trials in patients or volunteers by performing in vitro skin permeation studies, which can be used as a screening tool for formulation development. For skin permeation studies, an ATR-FTIR based setup proposed by Pellett et al. in 1997 and Russeau et al. in 2009 can be used instead of the traditional Franz cell. Significant improvements could be made to this setup to create the occluded environment specific to drug delivery systems. Quantitative analysis based on the spectral data can be performed using proprietary chemometric modeling methods. Furthermore, this method can also be used to measure the concentration of active ingredients dissolved in EthoGel formulations.
[0032] (In vitro permeation) Skin permeation tests can be performed using a Bruker ATR-FTIR instrument (Model Alpha; Bruker Optics Ltd., MA, USA) equipped with a 2 × 2 mm diamond spectral window. Pig abdominal skin samples can be obtained from a local meat supplier. Skin samples can be processed by removing fat and connective tissue from the dermal side, then cutting into pieces of 2 × 2 cm and storing at freezing temperature for later use. Furthermore, skin thickness can be measured before the experiment by warming the skin samples to room temperature and using a Material Thickness Meter (Model No. PCE-CT 26; PCE Americas Inc, Jupiter, FL, USA).
[0033] In a typical experiment, a skin sample is placed over the spectrometer's spectroscopic window with the dermis side facing the window. Additionally, approximately 1 g of EthoGel formulation may be applied to the stratum corneum side of the skin sample, which may be covered by an applicator having an area of approximately 3.5 square centimeters to minimize loss of penetration enhancer (i.e., ethanol) due to evaporation from the formulation. Additionally, approximately 1 gram of EthoGel formulation may be applied to the stratum corneum side of the skin sample, which may be covered by an applicator having an area of 3.5 square meters to minimize loss of penetration enhancer (i.e., ethanol) due to evaporation from the formulation. IR spectra are measured at 15-60 minute intervals and the experiment may continue for up to 72 hours if necessary. Additionally, the spectra can be used to calculate the w / w% of active ingredient (ibuprofen or diclofenac), ethanol, and glycerin on the dermis side of the skin. Chemometric modeling can be performed using software called Unscrambler (CAMO Software AS, Oslo, Norway). The diffusion coefficients of the active ingredients, ethanol, and glycerin can be calculated using Equation 1 below: where D is the diffusion coefficient (cm2 / H), L is the lag time (hours), and h is the skin thickness (cm). The lag times can be obtained from the plots in Figures 3 to 6 obtained with the EthoGel formulations described in Example 1 (ibuprofen) and Example 2 (diclofenac).
number
[0034] The flux J (μg / cm2 / H) was calculated using the following equation 2: where D is the diffusion coefficient, C is the concentration of the active ingredient dissolved in the EthoGel formulation (μg / mL), and h is the thickness of the skin.
number
[0035] EthoGel Formulation Example 1 For preparing this EthoGel formulation of ibuprofen at 1 kg scale, 400 g of ethanol, 105 g of glycerin, 200 g of water, and 30 g of polyethylene glycol may be mixed in a suitable container under stirring. Further, 3.5 g of sodium carbonate, 40.0 g of ibuprofen, 10.0 g of xanthan gum, and 2.0 g of carbomer may be added and the mixture may be dissolved / dispersed under stirring. Further, a homogenizer may be used to aid in the dispersion of the xanthan gum and / or carbomer, if necessary. Once the addition of all solid components is complete, stirring is continued for 30 minutes, after which the remaining amount of water (209.5 g) is added with slow stirring until the mixture becomes a homogenous gel. In vitro permeation testing of this formulation using porcine abdominal skin (thickness=0.19 cm) showed a permeation flux of ibuprofen of 283 μg / cm2 / H. Further, the EthoGel formulation of ibuprofen may be associated with the following composition: [Table 1]
[0036] EthoGel Formulation Example 2 For preparing this EthoGel formulation of diclofenac on a 1 kg scale, 388 g of ethanol, 200 g of glycerin, and 300 g of water may be mixed in a suitable container under stirring. Further, 7.0 g of sodium carbonate, 10.0 g of diclofenac, 8.0 g of xanthan gum, and 7.8 g of carbomer may be added and the mixture may be dissolved / dispersed under stirring. Further, if necessary, a homogenizer may be used to aid in the dispersion of the xanthan gum and / or carbomer. Once the addition of all solid ingredients is complete, the mixture may be stirred for 30 minutes, after which the remaining amount of water (79.2 g) may be slowly added with slow stirring until the mixture becomes a homogenous gel. In vitro permeation testing of this formulation using porcine abdominal skin (thickness=0.20 cm) showed a flux of diclofenac of 54 μg / cm2 / H. Further, the EthoGel formulation of diclofenac may be used in conjunction with the following compositions: [Table 2]
[0037] Now, reference is made to the figures. Figure 6 is a schematic diagram of a transdermal drug delivery system showing the structure of an applicator according to some embodiments. In this figure, the applicator 6 may include an oval-shaped disk applicator attached to the backing layer of a medical tape 4 in combination with a topical agent via an adhesive layer 5. The applicator 6 and the backing layer provide support and prevent the drug and other ingredients, especially volatile penetration enhancers, from passing through the surface of the delivery system. In addition, suitable materials for the backing layer include, for example, polyester, polyethylene terephthalate, certain nylons, polypropylene, metallized polyester films, polyvinylidene chloride, aluminum foil (Hoeck et al., U.S. Pat. No. 6,335,030), and the like. In addition, suitable materials for the adhesive layer 5 include, for example, acrylate polymers and polyisobutylene, and crosslinkers for carboxylic acid groups such as zinc oxide and magnesium oxide (Burton et al., U.S. Pat. No. 5,948,433).
[0038] Further, in some embodiments, the applicator 6 may be made of plastic and / or metal materials approved for pharmaceutical / medical device applications. Surrounding the edge of the applicator is a rim 3, the height of which may contain the topical formulation 7 and may be varied to optimize the effectiveness of the device in drug delivery. Within the circular rim 3, the surface of the applicator has blunt spikes 2 of various numbers, sizes, and shapes. The applicator 6 may be made of polymer and metal foil materials with a suitable thickness that maintains the desired shape while providing some flexibility. Suitable polymers include, for example, polyester, polycarbonate, polyethylene, polypropylene, polyvinyl chloride, polyethylene terephthalate, and the like. Suitable metal foils include, for example, aluminum and stainless steel. The height of the rim 3 may be about 600-3500 micrometers. The ratio of the height of the rim 3 to the height of the blunt spikes 2 may range from 0.5-1.5 and may be optimized based on the physical properties of the formulation and the site of application. When applied, the topical formulation 7 may fill the space between the spikes on the applicator and within the rim 3.
[0039] 7 is a close-up view of a transdermal drug delivery system showing placement of an applicator on a piece of medical tape, according to some embodiments. Thus, a portion of the medical tape 4 can be used to attach the applicator 6 to the skin of the user / patient. In this illustration, the medical tape 4 can be used to attach the applicator 6 to the skin of the user / patient.
[0040] FIG. 8 is a graphical representation showing in vitro skin permeation of ibuprofen using EthoGel formulation Example 1 and porcine abdominal skin, according to some embodiments.
[0041] FIG. 9 is a graphical representation showing in vitro skin permeation of ethanol using EthoGel formulation Example 1 and porcine abdominal skin, according to some embodiments.
[0042] FIG. 10 is a graphical representation showing in vitro skin permeation of glycerin using EthoGel formulation Example 1 and porcine abdominal skin, according to some embodiments.
[0043] FIG. 11 is a graphical representation showing in vitro skin permeation of diclofenac using EthoGel formulation Example 2 and porcine abdominal skin, according to some embodiments.
[0044] In a further embodiment, a transdermal drug delivery system for delivering a drug is disclosed. Moreover, the transdermal drug delivery system can include an applicator 6 attached to a backing layer of a medical tape 4 via an adhesive layer 5, and a topical formulation 7 containing an appropriate amount of a drug, which penetrates the skin after applying the system to the patient's skin.
[0045] Additionally, in some embodiments, topical formulation 7 is an EthoGel formulation that includes: (1) an active ingredient in a hydrogel-like carrier at a concentration appropriate for transdermal delivery of a given dose of drug, (2) two gelling agents that define the hydrogel-like physical properties of the carrier in the presence of (3) two skin penetration enhancers that also act as solvents / co-solvents, (4) a buffering agent to further enhance the solubility of the active ingredient in the formulation, (5) other stabilizers, and (6) various components in optimized ratios to maintain the chemical and physical stability of the drug delivery vehicle.
[0046] Additionally, in some embodiments, the applicator 6 may include a rim 3 that defines an enclosed space, and a blunt spike 2 that resides on the surface and in the space of the rim 3. Additionally, the topical formulation 7 may be loaded into the space between the spike and the rim 3 of the applicator 6. Additionally, the applicators 6 may have a variety of shapes and sizes and be optimized to deliver an appropriate amount of agent, with the blunt spike 2 serving the purpose of holding the topical formulation 7 and increasing the total surface area in contact with the skin when the system is applied to a patient.
[0047] In a further embodiment, a method for transdermal delivery of a drug is disclosed. The method may further include applying a transdermal drug delivery system to the skin of a patient. The transdermal drug delivery system may further include an applicator 6 attached to a backing layer of a medical tape 4 via an adhesive layer 5, and after application of the system to the skin of a patient, a topical formulation 7 of an appropriate amount of the drug penetrates the skin.
[0048] Further, in some embodiments, topical formulation 7 is an EthoGel formulation comprising: (1) an active ingredient in a hydrogel-like carrier at a concentration appropriate for transdermal delivery of a given dose of drug; (2) two gelling agents that define the hydrogel-like physical properties of the carrier, whose chemical / physical properties and amounts / ratios are optimized to allow the carrier to withstand the presence of high concentrations of organic solvents / co-solvents while maintaining its hydrogel-like physical properties; (3) two skin penetration enhancers that also act as solvents / co-solvents and play an important role in facilitating transdermal drug delivery; (4) other stabilizers; (5) a buffering agent that further enhances the solubility of the active ingredient in the formulation by adjusting the pH of the formulation; and (6) various components formulated in optimal ratios to maintain the chemical and physical stability of the drug delivery vehicle. Further, the hydrogel-like carrier may comprise two gelling agents, namely xanthan gum and carbomer, and various components known in the art, such as water as a solvent / co-solvent, a skin penetration enhancer, a second solvent / co-solvent, a preservative, a buffering agent, or a stabilizer. They are non-toxic and do not interact with other components of the composition.
[0049] Additionally, the skin penetration enhancer may include ethanol and glycerin, the amounts and ratios of which are adjusted to facilitate local or systemic distribution of the active ingredient. Additionally, the skin penetration enhancer may include other skin penetration enhancers known in the art, such as, for example, other alcohols, azone compounds, essential oils, sulfoxides, fatty acid esters (Hoeck et al., U.S. Patent No. 6,335,030).
[0050] Additionally, in some embodiments, the applicator 6 can include a rim 3 that defines an enclosed space, and a blunt spike 2 that resides on the surface and in the space of the rim 3. Additionally, the topical formulation 7 is loaded into the space of the applicator 6 between the blunt spike 2 and the rim 3. Additionally, the applicator 6 can have a variety of shapes and sizes and be optimized to deliver an appropriate amount of agent, with the blunt spike 2 serving the purpose of holding the topical formulation 7 and increasing the total surface area in contact with the skin when the system is applied to a patient.
[0051] Additionally, the EthoGel-Applicator transdermal drug delivery system (EGATDDS) described herein may be configured to deliver drugs at a much higher rate compared to conventional TD patches and / or conventional topicals for the following reasons: 1) The carrier of the EthoGel formulation is an "organogel" (organic gel) due to the presence of high concentrations of ethanol and glycerin, which are effective skin penetration enhancers, whereas conventional hydrogels utilize water as the main solvent. 2) The optimized EthoGel formulation reversibly changes the physiological properties of the skin SC layer (stratum corneum) to allow rapid penetration of the drug. 3) The applicator 6 creates an occlusive microenvironment and maintains the ethanol concentration in the carrier for a long period of time. 4) The applicator 6 can handle larger or adjustable amounts of the drug delivery system (i.e., EthoGel formulation). 5) The choice of vehicle is not limited to the type of adhesive system (as it is not an integral part of the delivery system). 6) The specially designed applicator 6 provides further opportunities to increase the skin contact area and decrease the penetration distance of the active ingredient.
[0052] In addition, EthoGel formulations7 of ibuprofen or diclofenac are prepared in the form of gels, the former for fever reduction in infants and the latter for acute or chronic pain management in arthritis patients. Other topical formulations of different active ingredients can be prepared, for example, in the form of creams, foams, lotions, ointments, which can be used for patients with different diseases, for example Alzheimer's disease.
[0053] As used herein, "a" or "an" means one or more (or at least one). For example, topical agent 7 may comprise a stabilizer and a buffering agent, in which case topical agent 7 may contain multiple stabilizers and multiple buffering agents. "About" or "About" is used herein to mean within 20% of the target point. For example, "about 600 micrometers to about 3500 micrometers" means a range of 480 micrometers to 720 micrometers to a range of 2800 micrometers to 4200 micrometers.
[0054] Although specific embodiments of the present disclosure have been described, other embodiments may exist. Additionally, the steps of the disclosed methods may be modified in any manner, including changing the order of steps and / or inserting or deleting steps, without departing from the present disclosure.
[0055] Although the present invention has been described in relation to its preferred embodiments, it should be understood that many other possible modifications and variations can be made without departing from the spirit and scope of the invention as hereinafter claimed.
Claims
1. A backing layer; An adhesive layer; A topical applicator; and The right amount of medication, and a suitable amount of a topical carrier; the backing layer is a medical tape; the topical applicator includes a flat applicator body, a plurality of blunt spikes, and a containment rim; said amount of drug and said amount of topical carrier being homogeneously mixed as a topical agent; the adhesive layer is disposed between the backing layer and the flat applicator body; the flat applicator body is connected to the backing layer by the adhesive layer across the backing layer; the containment rim and the plurality of blunt spikes are disposed adjacent the flat applicator body opposite the backing layer; the plurality of blunt spikes are connected onto the flat applicator body; the plurality of blunt spikes are distributed throughout the flat applicator body; the plurality of blunt spikes pointing away from the flat applicator body; the containment rim is connected to a periphery of the flat applicator body; the containment rim is disposed about the plurality of blunt spikes; the topical agent is retained within the containment rim; The topical agent is held between the plurality of blunted spikes. A transdermal drug delivery system for delivering a drug to a patient.
2. The backing layer is made of an impermeable material.
10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
3. The topical applicator is made of a polycarbonate material.
10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
4. the flat applicator body is sized and / or shaped to optimally deliver an appropriate amount of drug through the patient's skin; 10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
5. the peripheral shape of the flat applicator body is selected from the group consisting of a square shape, a rectangular shape, a circular shape, and an oval shape; 10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
6. the height of the containment rim of the flat applicator body is in the range of 600 micrometers to 3500 micrometers; 10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
7. the total number of said plurality of blunt spikes is configured to optimally deliver a suitable amount of drug through the patient's skin; 10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
8. The appropriate amount of the drug is a nonsteroidal anti-inflammatory drug (NSAID); 10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
9. said suitable amount of topical carrier being selected from the group consisting of a gel, a cream, a foam, a lotion, and an ointment; 10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
10. The topical carrier comprises an amount of at least one gelling agent, an amount of at least one skin penetration enhancer, an amount of at least one buffering agent, an amount of at least one stabilizer, and an amount of water; The at least one suitable amount of gelling agent, the at least one suitable amount of skin penetration enhancer, the at least one suitable amount of buffering agent, the at least one suitable amount of stabilizer, and the application amount of water are homogeneously mixed.
10. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 1.
11. the amount of drug is an amount of ibuprofen, the at least one gelling agent is an amount of xanthan gum and an amount of carbomer, the at least one skin penetration enhancer is an amount of ethanol and an amount of glycerin, the at least one buffer is an amount of sodium carbonate, and the at least one stabilizer is an amount of polyethylene glycol.
11. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 10.
12. the amount of ibuprofen is about 4.0 weight percent of the topical agent, the amount of water is about 41.0 weight percent of the topical agent, the amount of xanthan gum is about 1.0 weight percent of the topical agent, the amount of carbomer is about 0.2 weight percent of the topical agent, the amount of ethanol is about 40.0 weight percent of the topical agent, the amount of glycerin is about 10.5 weight percent of the topical agent, the amount of sodium carbonate is about 0.35 weight percent of the topical agent, and the amount of polyethylene glycol is about 3.0 weight percent of the topical agent.
12. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 11.
13. the amount of drug is an amount of diclofenac, the amount of at least one gelling agent is an amount of xanthan gum and an amount of carbomer, the amount of at least one skin permeation enhancer is an amount of ethanol and an amount of glycerin, and the amount of at least one buffering agent is an amount of sodium carbonate.
11. A transdermal drug delivery system for delivering a drug to a patient as claimed in claim 10.
14. the amount of diclofenac is about 1.0 weight percent of the topical agent, the amount of water is about 37.92 weight percent of the topical agent, the amount of xanthan gum is about 0.80 weight percent of the topical agent, the amount of carbomer is about 0.78 weight percent of the topical agent, the amount of ethanol is about 38.8 weight percent of the topical agent, the amount of glycerin is about 20.0 weight percent of the topical agent, and the amount of sodium carbonate is about 0.70 weight percent of the topical agent.
14. A transdermal drug delivery system for delivering a drug to a patient according to claim 13.
